Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
1. TLX101 shows promising data in Phase 2 IPAX-Linz trial for glioblastoma. 2. Patients showed median overall survival of 12.4 months with TLX101 therapy. 3. Study has no serious adverse events reported, indicating good safety profile. 4. Preliminary efficacy aligns with IPAX-1 results, supporting further investigation. 5. FDA filing for TLX101 expected in early 2025, with potential for U.S. trials.